Should aripiprazole be used instead of fluoxetine as first‑line therapy for depression?

Fluoxetine Should Be Used as First-Line Therapy for Depression, Not Aripiprazole

Fluoxetine (or another second-generation antidepressant) should be the first-line treatment for major depressive disorder, not aripiprazole. Aripiprazole is FDA-approved and evidence-based only as an augmentation strategy for treatment-resistant depression, not as initial monotherapy.

Rationale Based on Guidelines and FDA Labeling

The 2023 American College of Physicians systematic review and network meta-analysis 1 clearly positions second-generation antidepressants (including fluoxetine) as first-step treatments for moderate to severe major depressive disorder. The guideline evidence demonstrates that aripiprazole's role is specifically as a second-step augmentation strategy when patients fail to achieve remission after adequate trials of antidepressants.

The FDA labeling for aripiprazole 2 does not include approval for first-line monotherapy in depression. The drug carries a black box warning regarding increased suicidality risk in children, adolescents, and young adults being treated with antidepressants, and explicitly states: "It should be noted that aripiprazole is not approved as a single agent for treatment of depression" 2.

Evidence for Second-Step Use Only

The guideline evidence 1 specifically addresses aripiprazole in the context of augmentation strategies for patients who have already failed initial antidepressant treatment. One high risk-of-bias trial showed aripiprazole augmentation achieved higher remission rates than bupropion augmentation (55.4% vs. 34.0%) when added to ongoing antidepressant therapy—not as monotherapy.

The STAR*D trial data referenced in the guidelines 1 evaluated various second-step strategies after 12 weeks of failed citalopram treatment, positioning aripiprazole clearly in the treatment-resistant context.

Limited Research Supporting First-Line Use

While one small case note review 3 reported a 59% remission rate with aripiprazole as first-line therapy in late-life depression (54 patients, uncontrolled design), this represents low-quality evidence that cannot override guideline recommendations and FDA labeling. The study itself acknowledges the lack of controlled trials and calls for such research before changing practice patterns.

Safety and Tolerability Considerations

Antidepressants generally have better tolerability profiles than antipsychotics for depression treatment. The ACP guidelines 1 note that "participants treated with antidepressants, however, often had higher risks for adverse events or treatment discontinuation because of adverse events than patients receiving nonpharmacologic options"—but this comparison is between antidepressants and psychotherapy, not antipsychotics.

Aripiprazole carries risks of:

• Neuroleptic malignant syndrome 2
• Tardive dyskinesia 2
• Metabolic effects
• Extrapyramidal symptoms
• Pathological gambling and compulsive behaviors 2

These risks are acceptable when treating treatment-resistant depression where benefits outweigh harms, but are not justified as first-line therapy when safer, equally effective options exist.

Clinical Algorithm

For newly diagnosed major depressive disorder:

1. Start with a second-generation antidepressant (fluoxetine, sertraline, escitalopram, etc.) as first-line therapy
2. Optimize dose and allow adequate trial duration (typically 8-12 weeks)
3. If inadequate response after adequate trial: Consider second-step strategies including:
   • Switch to different antidepressant
   • Augment with aripiprazole (optimal dose 2-5 mg based on meta-analysis 4)
   • Augment with bupropion or other agents
   • Add cognitive behavioral therapy

Exception: The only scenario where aripiprazole might be considered earlier is in late-life depression with specific contraindications to multiple antidepressants, but this remains off-label and should be approached cautiously given limited evidence 3.

Key Pitfalls to Avoid

• Do not use aripiprazole as monotherapy for first-episode depression—this is off-label and lacks supporting evidence
• Do not bypass standard antidepressant trials based on small uncontrolled studies
• Do not expose patients to antipsychotic risks when safer first-line options are available and equally effective
• Remember that aripiprazole's role in bipolar depression 5, 6 does not translate to unipolar major depressive disorder first-line treatment